Results 11 to 20 of about 907 (150)

Circulating DNA fragmentomics and cancer screening

Cell Genomics, 2023
Summary: The high fragmentation of nuclear circulating DNA (cirDNA) relies on chromatin organization and protection or packaging within mononucleosomes, the smallest and the most stabilized structure in the bloodstream.
A R Thierry
exaly   +6 more sources

Cell-Free DNA Fragmentomics in Liquid Biopsy

Diagnostics, 2022
Cell-free DNA (cfDNA) in bodily fluids has rapidly transformed the development of noninvasive prenatal testing, cancer liquid biopsy, and transplantation monitoring. Plasma cfDNA consists of a mixture of molecules originating from various bodily tissues.
Spencer C Ding, Y M Dennis Lo, Y M Dennis Lo   +2 more
exaly   +5 more sources

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels. [PDF]

Nat Commun
Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically.
Helzer KT, Sharifi MN, Sperger JM, Chrostek MR, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause H, Schehr J, Sethakorn N, Kosoff D, Kyriakopoulos CE, Bassetti M, Blitzer G, Floberg J, Sjöström M, Armstrong AJ, Beltran H, McKay RR, Feng FY, O'Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG.   +26 more
europepmc   +5 more sources

DECIPHER-PRAD: an advanced fragmentomics-based cell-free DNA assay for prostate cancer early detection. [PDF]

Cell Commun Signal
Early detection of prostate cancer is limited by the poor specificity of prostate-specific antigen (PSA)-based screening. Cell-free DNA (cfDNA) fragmentomics offers a promising non-invasive approach to improve screening accuracy and risk stratification ...
Zhang S, Zhu G, Xu L, Zhang Q, Qiu X, Bao H, Wu M, Zhao X, Ding T, Wang F, Chang S, Shao Y, Zhuang J, Guo H.   +13 more
europepmc   +3 more sources

A multi-center study for colorectal cancer early detection in high-risk disease patients using cell-free fragmentomics assay. [PDF]

Cancer Cell Int
Background Early detection of colorectal cancer (CRC) is crucial for improving patient survival. This innovative multi-center study aims to develop a non-invasive blood-based assay using cell-free DNA (cfDNA) fragmentomics to differentiate CRC from ...
Chen J, Zheng Z, Zhang L, Lam W, Xie Q, Xu L, Zhou J, Zheng G, Zhu F, Wang K, Lyu Z, Yuan Q, Yang R, Xu X, Zhu D, Yang L, Bao H, Wu D, Li Y, Ding C, Gu B.   +20 more
europepmc   +3 more sources

Quantitative fragmentomics allow affinity mapping of interactomes [PDF]

Nature Communications, 2022
Protein networks have been widely explored but most binding affinities remain unknown, limiting the quantitative interpretation of interactomes. Here the authors measure affinities of 65,000 interactions involving human PDZ domains and target sequence ...
Gergo Gogl, Boglarka Zambo, Camille Kostmann, Alexandra Cousido-Siah, Bastien Morlet, Fabien Durbesson, Luc Negroni, Pascal Eberling, Pau Jané, Yves Nominé, Andras Zeke, Søren Østergaard, Élodie Monsellier, Renaud Vincentelli, Gilles Travé   +14 more
doaj   +4 more sources

Fragmenting the future with FLARE: a comprehensive fragmentomics pipeline based on long-read nanopore sequencing. [PDF]

Front Genet
PurposeCell-free DNA (cfDNA) fragmentation patterns carry biological information beyond fragment length, revealing nuclease activity, chromatin organization, and tissue of origin.
Ficorilli M, Lucchetta M, Lenoci D, Rolli I, Farina N, Cristofaro V, Giannini L, Ottini A, Deganello A, Cavalieri S, Licitra L, De Cecco L.   +11 more
europepmc   +2 more sources

Cell-free nucleic acid fragmentomics: A non-invasive window into cellular epigenomes

Translational Oncology
Clinical genomic profiling of cell-free nucleic acids (e.g. cell-free DNA or cfDNA) from blood and other body fluids has ushered in a new era in non-invasive diagnostics and treatment monitoring strategies for health conditions and diseases such as ...
Subhajyoti De
exaly   +3 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell-free DNA. [PDF]

Mol Oncol
Liquid biopsies containing circulating tumor DNA (ctDNA) are important biomarkers across several forms of cancer. The detection of mutations in cell‐free DNA (cfDNA) indicates the presence of ctDNA.
Maansson CT, Nielsen AL, Sorensen BS.
europepmc   +2 more sources

Liquid Biopsy in Early Screening of Cancers: Emerging Technologies and New Prospects. [PDF]

Biomedicines
Liquid biopsy is moving beyond mutation-centric assays to multimodal frameworks that integrate cell-free DNA (cfDNA) signals with additional analytes such as circulating tumor cells (CTCs) and extracellular vesicles (EVs).
Zhu H, Li Z, Xie K, Kassim SH, Cao C, Huang K, Lu Z, Ma C, Li Y, Jiang K, Yin L.   +10 more
europepmc   +2 more sources